202 related articles for article (PubMed ID: 14984374)
1. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis.
Miner P; Wedel M; Bane B; Bradley J
Aliment Pharmacol Ther; 2004 Feb; 19(3):281-6. PubMed ID: 14984374
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
Miner PB; Wedel MK; Xia S; Baker BF
Aliment Pharmacol Ther; 2006 May; 23(10):1403-13. PubMed ID: 16669955
[TBL] [Abstract][Full Text] [Related]
3. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.
van Deventer SJ; Wedel MK; Baker BF; Xia S; Chuang E; Miner PB
Aliment Pharmacol Ther; 2006 May; 23(10):1415-25. PubMed ID: 16669956
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.
Miner PB; Geary RS; Matson J; Chuang E; Xia S; Baker BF; Wedel MK
Aliment Pharmacol Ther; 2006 May; 23(10):1427-34. PubMed ID: 16669957
[TBL] [Abstract][Full Text] [Related]
5. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.
van Deventer SJ; Tami JA; Wedel MK
Gut; 2004 Nov; 53(11):1646-51. PubMed ID: 15479686
[TBL] [Abstract][Full Text] [Related]
6. Vedolizumab for the Treatment of Chronic Pouchitis.
Travis S; Silverberg MS; Danese S; Gionchetti P; Löwenberg M; Jairath V; Feagan BG; Bressler B; Ferrante M; Hart A; Lindner D; Escher A; Jones S; Shen B;
N Engl J Med; 2023 Mar; 388(13):1191-1200. PubMed ID: 36988594
[TBL] [Abstract][Full Text] [Related]
7. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
Nguyen N; Zhang B; Holubar SD; Pardi DS; Singh S
Cochrane Database Syst Rev; 2019 Nov; 11(11):CD001176. PubMed ID: 31785173
[TBL] [Abstract][Full Text] [Related]
8. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
Nguyen N; Zhang B; Holubar SD; Pardi DS; Singh S
Cochrane Database Syst Rev; 2019 May; 5(5):CD001176. PubMed ID: 31136680
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of bismuth carbomer enemas in patients with treatment-resistant chronic pouchitis.
Gionchetti P; Rizzello F; Venturi A; Ferretti M; Brignola C; Peruzzo S; Belloli C; Poggioli G; Miglioli M; Campieri M
Aliment Pharmacol Ther; 1997 Aug; 11(4):673-8. PubMed ID: 9305474
[TBL] [Abstract][Full Text] [Related]
10. Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis.
Greuter T; Vavricka SR; Biedermann L; Pilz J; Borovicka J; Seibold F; Sauter B; Rogler G
Dig Dis; 2018; 36(2):123-129. PubMed ID: 29207381
[TBL] [Abstract][Full Text] [Related]
11. Alicaforsen in the treatment of pouchitis.
Greuter T; Rogler G
Immunotherapy; 2017 Nov; 9(14):1143-1152. PubMed ID: 29067882
[TBL] [Abstract][Full Text] [Related]
12. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
Yacyshyn BR; Barish C; Goff J; Dalke D; Gaspari M; Yu R; Tami J; Dorr FA; Sewell KL
Aliment Pharmacol Ther; 2002 Oct; 16(10):1761-70. PubMed ID: 12269969
[TBL] [Abstract][Full Text] [Related]
13. Alicaforsen for the treatment of inflammatory bowel disease.
Jairath V; Khanna R; Feagan BG
Expert Opin Investig Drugs; 2017 Aug; 26(8):991-997. PubMed ID: 28670932
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis.
Shen B; Pardi DS; Bennett AE; Queener E; Kammer P; Hammel JP; LaPlaca C; Harris MS
Am J Gastroenterol; 2009 Jun; 104(6):1468-74. PubMed ID: 19436282
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis.
Vegter S; Tolley K; Wilson Waterworth T; Jones H; Jones S; Jewell D
Aliment Pharmacol Ther; 2013 Aug; 38(3):284-93. PubMed ID: 23750909
[TBL] [Abstract][Full Text] [Related]
16. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
Singh S; Stroud AM; Holubar SD; Sandborn WJ; Pardi DS
Cochrane Database Syst Rev; 2015 Nov; (11):CD001176. PubMed ID: 26593456
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.
Yacyshyn B; Chey WY; Wedel MK; Yu RZ; Paul D; Chuang E
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):215-20. PubMed ID: 17296530
[TBL] [Abstract][Full Text] [Related]
18. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Shen B; Achkar JP; Lashner BA; Ormsby AH; Remzi FH; Brzezinski A; Bevins CL; Bambrick ML; Seidner DL; Fazio VW
Inflamm Bowel Dis; 2001 Nov; 7(4):301-5. PubMed ID: 11720319
[TBL] [Abstract][Full Text] [Related]
19. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis.
Shen B; Achkar JP; Lashner BA; Ormsby AH; Brzezinski A; Soffer EE; Remzi FH; Bevins CL; Fazio VW
Am J Gastroenterol; 2002 Apr; 97(4):972-7. PubMed ID: 12003434
[TBL] [Abstract][Full Text] [Related]
20. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells.
Pronio A; Montesani C; Butteroni C; Vecchione S; Mumolo G; Vestri A; Vitolo D; Boirivant M
Inflamm Bowel Dis; 2008 May; 14(5):662-8. PubMed ID: 18240282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
